Navigation Links
Difficult to Treat Erectile Dysfunction Patients
Date:1/6/2008

Real Medicine Now

CHERRY HILL, N.J., Jan. 7 /PRNewswire/ -- TriMix Laboratories LLC today announced the introduction of TriMix-gel(TM). TriMix-gel(TM) has been suggested as an alternative for patients who fail on Viagra(R) type pills and cannot or will not self inject with a needle. With twenty million American men currently suffering with ED, current treatments are sufficient in many cases, but there remain more and more men who can't tolerate the side effects of Viagra(R) type pills and cannot bring themselves to self inject with a needle.

TriMix-gel(TM) is not an herbal remedy. It contains prescription medications listed in the US Pharmacopoeia. The active ingredients in this compounded medicine, prostaglandin, papaverine and phentolamine, have been tested and widely prescribed by physicians for many years.

Typically, trimix for injection would have to be refrigerated and then self injected at time of use. But this new compound in gel form called TriMix- gel(TM), allows the patient to carry the medicine on his person at room temperature. More importantly, an ED patient will not have to use a needle to self inject himself before sexual intercourse.

TriMix-gel(TM) doesn't require needles because it uses a novel methodology. At the time of use, before sexual intercourse, the patient uses an "all-in-one" application device which stores, mixes and applies the medicine. The patient does not need a needle for self injection. And the medicine does not require refrigeration.

To obtain the medicine, a patient needs to visit his physician for a thorough ED examination and if appropriate, the patient will be prescribed this medicine by his own doctor. The doctor can fax the prescription to the pharmacy (877-387-4649) and the pharmacy will ship the medicine directly to the patient. Applied Pharmacy Services, Inc., a licensed pharmacy in Mobile, AL has been chosen as the exclusive compounding pharmacy for TriMix-gel(TM) (877-887-4649).

T.J. Harkins, President of TriMix Laboratories says, "Physicians have been looking for a new delivery method for these medications for a long time and TriMix-gel(TM) is exactly what ED patients have been asking for."

The profession of pharmacy has always been based on the patient-physician- pharmacist relationship, known as the "Triad." Through this "Triad" relationship, patient needs are determined by a physician, who chooses a treatment regimen that may include a compounded medication. Physicians often prescribe compounded medications for various reasons, such as when a patient cannot ingest a medication in its available form. A pharmacist can prepare the medication in cream, liquid, gel or other form that the patient can more easily take.

TriMix Laboratories LLC is a medical research and marketing firm specializing in the urological subspecialty of erectile dysfunction. Applied Pharmacy is a recognized leader in pharmaceutical compounding, helping Physicians and Veterinarians with medicine precisely customized for each individual patient. Applied Pharmacy maintains federal and state licenses and permits and is registered to dispense in almost all states. For more information, visit http://www.TriMix-gel.com.

This press release contains forward-looking statements. These statements involve risks and uncertainties which may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed and actual results may differ materially. Ingredients in TriMix- gel(TM) are FDA approved but TriMix-gel(TM) is a custom compound made in a pharmacy and therefore has not been approved by the FDA for treatment of ED. TriMix-gel(TM) requires a valid prescription from a physician. You should discuss the risks and side effects associated with this drug with your physician. Before taking any action, consult your physician.

Contact:

TJ Harkins

TriMix Laboratories

Cherry Hill, NJ

856-755-3600


'/>"/>
SOURCE TriMix Laboratories LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IBM and Imago find a crucial difficulty in semiconductor device scaling
2. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
10. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
11. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... NextSteps 2017, NetDimensions’ annual global user ... this May on the following dates: , ?    London, UK from May 10-11, ?    New ... and Performance Institute will be the opening keynote speaker at the NextSteps ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... is pleased to announce the company is now a certified iMedNet eClinical and ... software certification enables the company’s clinical research team to build, customize and manage ...
(Date:4/24/2017)... ... April 24, 2017 , ... It is ... cellular milieu; however, the broad application of this cellular target engagement concept to ... quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular applications, but ...
(Date:4/21/2017)... and BELLINGHAM, Washington, USA (PRWEB) , ... April ... ... technologies for sensing, imaging, and related applications were the focus of researchers, engineers, ... Commercial Sensing 2017 in Anaheim. , Sponsored by SPIE, the international ...
Breaking Biology Technology:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/23/2017)... 2017 The report "Gesture Recognition and Touchless Sensing Market ... - Global Forecast to 2022", published by MarketsandMarkets, the market is expected to ... between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... 2017 Vigilant Solutions , a vehicle ... agencies, announced today the appointment of retired FBI special ... safety business development. Mr. Sheridan brings more ... a focus on the aviation transportation sector, to his ... Mr. Sheridan served as the Aviation Liaison Agent Coordinator ...
Breaking Biology News(10 mins):